Gilead's Twice-Yearly HIV Shot Called 'Closest Thing to a Vaccine' — But Access Remains Uncertain

A drug described as the 'closest thing to an HIV vaccine'

A twice-yearly injection from Gilead Sciences is being described, according to Al Jazeera's reporting, as the closest thing available to an HIV vaccine. The report, by Al Jazeera's Mikail Malik, frames the central question not as whether the drug works, but as who actually gets access to it.

Al Jazeera's coverage describes the emergence of this injectable prevention option as something that could transform HIV prevention — but notes that access to it raises bigger questions about public money, pharmaceutical power, drug prices, and shrinking global health funding.

Who gets it remains the open question

According to the Al Jazeera report, the fight over access to this drug touches on several unresolved tensions: how public money factors into a drug's development, how much pricing power pharmaceutical companies hold, what drug prices ultimately become, and how shrinking global health funding affects distribution.

The report does not resolve these questions. It instead frames them as the fight now underway — one that will determine whether a prevention breakthrough translates into broad access or remains limited by financial and political constraints.

What's unresolved

Al Jazeera's reporting does not provide final figures on pricing, licensing terms, regulatory status, or funding levels tied to this drug. The specifics of who will be able to access it, on what terms, and under what funding arrangements remain open questions without a confirmed timeline, based on the available reporting.